- Home
- BMEA vs RENB Comparison
BMEA vs RENB Comparison
Compare BMEA & RENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- RENB
- Stock Information
- Founded
- BMEA 2017
- RENB 2011
- Country
- BMEA United States
- RENB United States
- Employees
- BMEA N/A
- RENB N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- RENB Biotechnology: Pharmaceutical Preparations
- Sector
- BMEA Health Care
- RENB Health Care
- Exchange
- BMEA Nasdaq
- RENB Nasdaq
- Market Cap
- BMEA 65.8M
- RENB 62.0M
- IPO Year
- BMEA 2021
- RENB N/A
- Fundamental
- Price
- BMEA $1.93
- RENB $0.27
- Analyst Decision
- BMEA Strong Buy
- RENB
- Analyst Count
- BMEA 10
- RENB 0
- Target Price
- BMEA $22.30
- RENB N/A
- AVG Volume (30 Days)
- BMEA 2.3M
- RENB 2.2M
- Earning Date
- BMEA 07-30-2025
- RENB 05-15-2025
- Dividend Yield
- BMEA N/A
- RENB N/A
- EPS Growth
- BMEA N/A
- RENB N/A
- EPS
- BMEA N/A
- RENB N/A
- Revenue
- BMEA N/A
- RENB N/A
- Revenue This Year
- BMEA N/A
- RENB N/A
- Revenue Next Year
- BMEA N/A
- RENB N/A
- P/E Ratio
- BMEA N/A
- RENB N/A
- Revenue Growth
- BMEA N/A
- RENB N/A
- 52 Week Low
- BMEA $1.29
- RENB $0.26
- 52 Week High
- BMEA $13.07
- RENB $2.10
- Technical
- Relative Strength Index (RSI)
- BMEA 50.04
- RENB 38.03
- Support Level
- BMEA $1.58
- RENB $0.33
- Resistance Level
- BMEA $2.03
- RENB $0.32
- Average True Range (ATR)
- BMEA 0.15
- RENB 0.03
- MACD
- BMEA -0.00
- RENB -0.00
- Stochastic Oscillator
- BMEA 80.00
- RENB 4.84
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.